Manufacturing & Packaging

The pandemic has accelerated the adoption of enterprise resource planning in pharma supply chain management, as the recent US rise of one “technology enabler” attests

Company officials predict 500 million vaccine doses per year to be produced via the center, which will offer fill-finish, packaging services

Company officials believe new facility will help meet ongoing demand for temperature-controlled packaging

Manufacturing facility to provide 1.5 million square feet of bioproduction technologies

Recent FDA actions may finally usher in access boost to follow-on biologics in the US

R&D partnership with VaxEquity outlines plan to use saRNA as a go-to therapeutic

The steps pharma manufacturers can take to mitigate transportation costs amid Covid’s supply-chain crunch

Financial commitment expected to expand the development and commercialization pipeline for new medicines

Deal is dependent on FDA approval of Phathom’s vonoprazan compound

Five-year, nearly $90 million deal revolves around bulk drug substance formulation for Providence’s future shot

Expansion at German facility features new GMP manufacturing lines and a cleanroom, among other additions

Latest construction plan continues CDMO’s vision for biopharma expansion

CDMO’s objective is to cater to various market segments in order to meet microbial bio-manufactured compound demand

After previously going bankrupt, center is now under US ownership for the first time

Swiss organization will take patient-centric approach towards developing injectables

Company’s prospective malaria and tuberculosis doses will be developed in Rwanda, Senegal

Irvine, CA, location will house 40,000 square feet of oral solid dosage forms

Swiss CDMO’s expansion at recently opened Guangzhou plant expected to be ready by next year

Venture anticipated to more than double single-use bioreactor mammalian cell-culture capacity on site

CDMO's expansion of Rensselaer, NY, facility will help grow its API division

Acquisition addresses the need for meeting healthcare sector’s patient support demand

Cardiff center will help produce lipids that are necessary for mRNA Covid vaccines

Developments include the creation of a new microbial facility, expansion of mammalian center

Deal allows for bicoastal expansion of pharmaceutical services

End result is an enhanced method for developing vaccinia capping enzyme (VCE), parties say